# Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism

> **NCT03757923** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Dow University of Health Sciences** · enrollment: 110 (estimated)

## Conditions studied

- Menstrual Irregularities
- Hyperandrogenism

## Interventions

- **DRUG:** TAB METFORMIN
- **DRUG:** TAB PIOGLITAZONE

## Key facts

- **NCT ID:** NCT03757923
- **Lead sponsor:** Dow University of Health Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-18
- **Primary completion:** 2018-12-17
- **Final completion:** 2019-01
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2018-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03757923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03757923, "Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03757923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*